Last reviewed · How we verify
Hydroxychloroquine + low-dose prednisone
Hydroxychloroquine suppresses immune activation and inflammatory responses, while low-dose prednisone provides additional anti-inflammatory and immunosuppressive effects.
Hydroxychloroquine suppresses immune activation and inflammatory responses, while low-dose prednisone provides additional anti-inflammatory and immunosuppressive effects. Used for Systemic lupus erythematosus (SLE), Rheumatoid arthritis, Other autoimmune or inflammatory conditions.
At a glance
| Generic name | Hydroxychloroquine + low-dose prednisone |
|---|---|
| Also known as | Experimental Arm |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Antimalarial + corticosteroid combination |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Hydroxychloroquine is an antimalarial agent that accumulates in lysosomes and inhibits toll-like receptor signaling and antigen presentation, reducing T-cell and B-cell activation. Low-dose prednisone, a corticosteroid, suppresses inflammatory cytokine production and immune cell proliferation. Together, this combination targets multiple pathways in autoimmune and inflammatory diseases.
Approved indications
- Systemic lupus erythematosus (SLE)
- Rheumatoid arthritis
- Other autoimmune or inflammatory conditions
Common side effects
- Gastrointestinal disturbance
- Headache
- Retinopathy (hydroxychloroquine)
- Immunosuppression-related infections
- Osteoporosis (prednisone)
- Hyperglycemia
Key clinical trials
- The Effect of Curcumin on the Clinical Outcome of Pediatric Patients with Active Lupus Nephritis (PHASE2)
- Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis (PHASE3)
- Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 (NA)
- Immunosuppressant Regimens for Living Fetuses Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: